Annual Meeting of Shareholders 2024

Marc N. Casper

Chairman, President and Chief Executive Officer

Julia L. Chen

Vice President and Corporate Secretary

The world leader in serving science

Proprietary | May 22, 2024

Annual Meeting of Shareholders

Meeting Agenda

  • Call to Order and Instructions
  • Voting Items
  • Questions and Answers on Voting Matters
  • Closing of Polls
  • Preliminary Voting Report
  • Management Presentation
  • Questions and Answers
  • Adjournment

2 Proprietary | May 22, 2024

Annual Meeting of Shareholders

Safe Harbor Statement

Various remarks that we may make about the Company's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Company's most recent Annual Report on Form 10-K under the caption "Risk Factors," which is on file with the Securities and Exchange Commission and available in the "Investors" section of our website under the heading "SEC Filings." While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Non-GAAP Measures

During this presentation, we will be referring to certain financial measures not prepared in accordance with generally accepted accounting principles, or GAAP. The non-GAAP financial measures of Thermo Fisher's results of operations and cash flows included in this presentation are not meant to be considered superior to or a substitute for Thermo Fisher's results of operations prepared in accordance with GAAP. Definitions of these non-GAAP financial measures, as well as, for historical periods, a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures, are available as an

appendix to this presentation, which can be found under "News & Events" in the "Investors" section of our website,

thermofisher.com.

3 Proprietary | May 22, 2024

Annual Meeting of Shareholders

Voting Matters

  • Proposal 1: Election of Directors
  • Proposal 2: Approval of an Advisory Vote on Executive Compensation
  • Proposal 3: Ratification of the Selection of the Independent Auditors for 2024
  • Proposal 4: Shareholder Proposal to Adopt a Simple Majority Vote

4 Proprietary | May 22, 2024

Questions

Annual Meeting of Shareholders 2024

5 Proprietary | May 22, 2024

Annual Meeting of Shareholders

Voting Matters

  • Proposal 1: Election of Directors
  • Proposal 2: Approval of an Advisory Vote on Executive Compensation
  • Proposal 3: Ratification of the Selection of the Independent Auditors for 2024
  • Proposal 4: Shareholder Proposal to Adopt a Simple Majority Vote

6 Proprietary | May 22, 2024

Company Overview Annual Meeting of Shareholders 2024

Marc N. Casper

Chairman, President and Chief Executive Officer

The world leader in serving science

Proprietary | May 22, 2024

The world leader in serving science

$43B

>120,000

$1.3B

revenue

colleagues

R&D investment

Industry-leading scale

Unmatched depth of capabilities

Sustainable value creation

Exceptional commercial reach

Leading innovative

Comprehensive biopharma

Positive societal impact

Unique customer access

technologies

services offering

Comprehensive ESG strategy

Extensive global footprint

Deep applications

Premier productivity partner

expertise

Powered by our Practical Process Improvement (PPI) Business System

8 NOTE: Amounts based on Q1 2024 TTM

Our Mission is our purpose

We enable our customers to make the world healthier, cleaner and safer

9

Very attractive revenue profile

Leadership in fast-growing end markets

Enabling advanced materials to power the digital economy and the clean

Very strong

Unparalleled

recurring revenue mix

commercial engine

energy transition

Industrial

& Applied

Enabling

13%

Precision

Diagnostics

Medicine

& Healthcare

End

Pharma

15%

& Biotech

markets

57%

Academic &

Government

15%

Powering the

Golden Age of

Biology

10 NOTE: Revenue and percentages based on unaudited TTM through Q1 2024

Instruments

17%

Products

Services & consumables

83%

Revenue: $42.5B

ROW

4%

Asia-Pacific

18%

North

Regions America

53%

Europe

25%

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Thermo Fisher Scientific Inc. published this content on 22 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 May 2024 13:14:07 UTC.